
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Target Identification</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header><h1>Target Identification</h1></header>
  <nav><a href="index.html">Back to Home</a></nav>

<main>
    <section>
      <h2>What is Target Identification?</h2>
      <p>Target identification is the first and foundational step in the drug discovery process. It involves recognizing a biological entity—typically a gene, protein, or pathway—that plays a critical role in the onset or progression of a disease. The goal is to find a “druggable” target whose modulation can yield therapeutic benefits.</p>
    </section>

    <section>
      <h2>Basic Concepts</h2>
      <ul>
        <li><strong>Biological Targets:</strong> Proteins, genes, RNA molecules, and signaling pathways.</li>
        <li><strong>Disease Association:</strong> Targets must be causally linked to disease mechanisms.</li>
        <li><strong>Druggability:</strong> A target is druggable if it has a binding site suitable for small molecules or biologics.</li>
      </ul>
    </section>

    <section>
      <h2>Intermediate Concepts</h2>
      <ul>
        <li><strong>Target Validation:</strong> Experimental confirmation using gene editing, overexpression, and pharmacological inhibition.</li>
        <li><strong>Omics Technologies:</strong> Genomics, transcriptomics, proteomics, and metabolomics for target discovery.</li>
        <li><strong>Bioinformatics & Systems Biology:</strong> Use of databases and network analysis to predict and prioritize targets.</li>
      </ul>
    </section>

    <section>
      <h2>Advanced Concepts</h2>
      <ul>
        <li><strong>Functional Genomics:</strong> High-throughput CRISPR screens and synthetic lethality studies.</li>
        <li><strong>Single-Cell Technologies:</strong> Single-cell RNA-seq and spatial transcriptomics.</li>
        <li><strong>AI and Machine Learning:</strong> Predicting target-disease associations and integrating multi-omics data.</li>
        <li><strong>Structural Biology:</strong> X-ray crystallography, Cryo-EM, and NMR for rational drug design.</li>
        <li><strong>Phenotypic Screening:</strong> Reverse pharmacology and observable cellular responses.</li>
      </ul>
    </section>

    <section>
      <h2>Challenges in Target Identification</h2>
      <ul>
        <li>Biological complexity and pathway redundancy</li>
        <li>Off-target effects and unintended interactions</li>
        <li>Tissue specificity and relevance</li>
        <li>Resistance mechanisms in cancer and infectious diseases</li>
      </ul>
    </section>

    <section>
      <h2>Real-World Examples</h2>
      <ul>
        <li><strong>BCR-ABL in CML:</strong> Led to imatinib (Gleevec), revolutionizing cancer therapy.</li>
        <li><strong>PCSK9 in hypercholesterolemia:</strong> Monoclonal antibodies for lipid management.</li>
        <li><strong>PD-1/PD-L1 in immuno-oncology:</strong> Immune checkpoint inhibitors like pembrolizumab.</li>
      </ul>
    </section>

    <section>
      <h2>Future Directions</h2>
      <ul>
        <li>Targeting the “undruggable” such as transcription factors</li>
        <li>Allosteric modulation and alternative binding sites</li>
        <li>Microbiome-derived molecule targeting</li>
        <li>Precision targeting using patient-specific data</li>
      </ul>
    </section>
  </main>

  <footer><p>&copy; 2025 Drug Discovery Knowledge Base</p></footer>
</body>
</html>
